Edwards Lifesciences Corporation $EW Stock Holdings Lessened by Smithbridge Asset Management Inc. DE

Smithbridge Asset Management Inc. DE lessened its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 49.9% in the first quarter, Holdings Channel.com reports. The fund owned 16,243 shares of the medical research company’s stock after selling 16,155 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Edwards Lifesciences were worth $1,301,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of EW. Root Financial Partners LLC lifted its holdings in shares of Edwards Lifesciences by 53.0% during the first quarter. Root Financial Partners LLC now owns 1,137 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 394 shares during the last quarter. Financial Life Planners purchased a new position in Edwards Lifesciences in the 1st quarter worth about $96,000. USS Investment Management Ltd raised its holdings in Edwards Lifesciences by 8.1% during the 1st quarter. USS Investment Management Ltd now owns 126,927 shares of the medical research company’s stock worth $10,165,000 after buying an additional 9,504 shares during the period. IFM Investors Pty Ltd lifted its stake in Edwards Lifesciences by 3.1% during the first quarter. IFM Investors Pty Ltd now owns 133,340 shares of the medical research company’s stock valued at $10,678,000 after buying an additional 3,954 shares in the last quarter. Finally, iA Global Asset Management Inc. acquired a new position in shares of Edwards Lifesciences in the first quarter worth about $574,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EW. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. TD Cowen reaffirmed a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Evercore reiterated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research report on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.39.

Edwards Lifesciences Stock Performance

EW stock opened at $91.95 on Thursday. The firm has a 50 day simple moving average of $85.06 and a 200 day simple moving average of $83.41. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $92.88. The stock has a market cap of $52.95 billion, a P/E ratio of 48.91, a P/E/G ratio of 2.27 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the business earned $0.64 EPS. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 58,977 shares of company stock valued at $4,921,803. 0.31% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.